Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
Recruitment status was Recruiting
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with bevacizumab and oxaliplatin may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side-effects and best dose of sorafenib when given together with bevacizumab and oxaliplatin and to see how well it works in treating patients with metastatic malignant melanoma.
Drug: sorafenib tosylate
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma|
- Maximum tolerated dose of sorafenib tosylate when administered with bevacizumab and oxaliplatin [ Designated as safety issue: Yes ]
- Response (complete and partial) as assessed by RECIST criteria [ Designated as safety issue: No ]
- Progression-free survival [ Designated as safety issue: No ]
- Overall survival [ Designated as safety issue: No ]
|Study Start Date:||May 2007|
|Estimated Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
- To determine the maximum tolerated dose of sorafenib tosylate when administered with bevacizumab and oxaliplatin.
- To determine the effect of this treatment regimen on the complete and partial response rate in patients with metastatic melanoma.
- To determine the effect of this treatment regimen on the progression-free and overall survival of patients with metastatic melanoma.
OUTLINE: This is a phase I dose-escalation study of sorafenib tosylate followed by a phase II study.
- Phase I: Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive oral sorafenib tosylate twice daily on days 1-14. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
- Phase II: Patients receive sorafenib tosylate at the maximum tolerated dose and bevacizumab and oxaliplatin as in phase I.
After completion of study therapy, patients are followed for at least 5 years.
|United States, California|
|San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas||Recruiting|
|Encinitas, California, United States, 92024|
|Contact: Edward F. McClay, MD 760-452-3340 firstname.lastname@example.org|
|Principal Investigator:||Edward F. McClay, MD||San Diego Pacific Oncology & Hematology Associates|